Stock Analiz

P3 Health Partners Inc. PIII

Medical/Nursing Services · IPO 2021 · data as of November 13, 2026

$2.70Market cap $560M
Open the interactive analysis →

P3 Health Partners Inc. (PIII) is a healthcare company listed in the US with a market value of about $560M. In the twelve months to September 30, 2026 it had revenue of $1.6B and net income of -$51M, a net margin of -3.3%.

Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is track record (2/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of 59% a year, a 5-year average ROIC of -349%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 12% below the current price.

About P3 Health Partners

P3 Health Partners is listed in the US and classified in medical/nursing services, IPO year 2021. Revenue went from $145M in 2019 to $1.5B in 2025, growth of about 46.9% a year. It was profitable in 0 of the last 6 years in our data. Its share count rose by 293% over three years (dilution for shareholders).

Score: 0.8 / 5

Value0/5
Future growth1/5
Track record2/5
Financial health0/5
Shareholder returns1/5

Checks passed

  • 3-year revenue growth above 10% a year
  • 5-year revenue growth above 8% a year
  • ROE above 15%
  • Stock-based pay below 5% of revenue

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • Profit margin improving
  • 3-year free cash flow growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S0.4
P/B5.1
EV/EBITDA237.3
PEG—
Dividend yield0.00%
FCF yield-20.7%
Shareholder yield0.0%
Intrinsic value vs. price−12%

Growth and quality

Revenue growth (1 yr)-2.8%
Revenue growth (5 yrs, per year)58.6%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-11.2%
ROIC (5-yr avg.)-348.6%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 6 years

Fiscal yearTTM202520242023202220202019
Revenue$1.6B$1.5B$1.5B$1.3B$1.0B$491M$145M
Net income-$51M-$148M-$136M-$58M-$270M-$31M-$42M
Free cash flow-$116M—-$110M-$78M-$128M-$28M-$30M
EPS (diluted)$-23.32$-45.26$-54.06$-31.50$-325.00——
Net margin-3.3%-10.1%-9.0%-4.6%-25.7%-6.4%-28.8%
ROIC—-161.7%-92.5%-49.7%-1090.6%——

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 1 analysts is $11.50, 326% above the current price; targets range from $11.50 to $11.50; the consensus rating is “Buy”; expected EPS is $-9.38 for the fiscal year ending December 31, 2026.

Frequently asked questions

Is P3 Health Partners stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 12% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does P3 Health Partners pay a dividend?

Not currently.

Is P3 Health Partners a good stock to buy?

We do not give buy or sell advice. P3 Health Partners scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.